 |
Technical Support
(877) SEPAX-US, press 3  TechSupport@sepax-tech.com |
  |
Search Results
Product
| Zenix-C SEC-300 - View more details | Sign In to see pricing, or order online |
| Zenix-C SEC phase comprises of uniform, hydrophilic, and neutral nanometer thick film chemically bonded to high purity and mechanically stabilized silica. |
| Part Number | Phase | Particle Size | Pore Size | ID×Length | Buy or Quote |
|---|---|---|---|---|---|
| 233300-10005 | Zenix-C SEC-300 | 3 µm | 300 Å | 10.0×50mm | |
| 233300-10015 | Zenix-C SEC-300 | 3 µm | 300 Å | 10.0×150mm | |
| 233300-10030 | Zenix-C SEC-300 | 3 µm | 300 Å | 10.0×300mm | |
| 233300-21205 | Zenix-C SEC-300 | 3 µm | 300 Å | 21.2×50mm | |
| 233300-21230 | Zenix-C SEC-300 | 3 µm | 300 Å | 21.2×300mm | |
| 233300-4605 | Zenix-C SEC-300 | 3 µm | 300 Å | 4.6×50mm | |
| 233300-4615 | Zenix-C SEC-300 | 3 µm | 300 Å | 4.6×150mm | |
| 233300-4630 | Zenix-C SEC-300 | 3 µm | 300 Å | 4.6×300mm | |
| 233300-7805 | Zenix-C SEC-300 | 3 µm | 300 Å | 7.8×50mm | |
| 233300-7815 | Zenix-C SEC-300 | 3 µm | 300 Å | 7.8×150mm | |
| 233300-7820 | Zenix-C SEC-300 | 3 µm | 300 Å | 7.8×200mm | |
| 233300-7830 | Zenix-C SEC-300 | 3 µm | 300 Å | 7.8×300mm | |
| 233300LS-4615 | Zenix-C SEC-300 | 3 µm | 300 Å | 4.6×150mm | |
| 233300LS-4630 | Zenix-C SEC-300 | 3 µm | 300 Å | 4.6×300mm | |
| 233300LS-7815 | Zenix-C SEC-300 | 3 µm | 300 Å | 7.8×150mm | |
| 233300LS-7830 | Zenix-C SEC-300 | 3 µm | 300 Å | 7.8×300mm | |
| 233300P-4605 | Zenix-C SEC-300 | 3 µm | 300 Å | 4.6×50mm | |
| 233300P-4630 | Zenix-C SEC-300 | 3 µm | 300 Å | 4.6×300mm | |
Application
| MAb and its ADCs Separation on SEC - View application note |
| Analytical Characterization of Antibody Drug Conjugates - View application note |
| SEC Packing Chemistry Impact on MAb Separation - View application note |
| ADC Analysis on Zenix-C SEC - View application note |
| Herceptin-Lysine ADC Analysis by Zenix-C and TSKgel - View application note |
| mPEG-peptide on Zenix and Zenix-C SEC - View application note |
| Analysis of Exenatide and Pegylated Exenatide on Zenix and Zenix-C SEC - View application note |
| Fusion Protein Separation on Zenix and Zenix-C 300 - View application note |
| HSA Fusion Protein Separation on Zenix and Zenix-C 300 - View application note |
| Fusion Protein Separation on SEC and SAX - View application note |
| Pegylated Protein Separation on SEC and SAX - View application note |
| DTT and EDTA Effect on SEC Protein Separation - View application note |
| 2.1 mm ID SEC for Protein Separation - View application note |
| Human Serum Separation on Zenix-C and SAX - View application note |
| MAb/ADC Fragment Separation after IDeS Digestion - View application note |
| Protein Standards on Zenix-C and SRT-C SEC-300 - View application note |
| Intact MAb, ADC and their Fragment Analysis with SEC-MS - View application note |
| Literature Reference: Hiding Payload Inside the IgG Fc Cavity Significantly Enhances the Therapeutic Index of Antibody Drug Conjugates - View application note |
| Complex Protein Sample Mixtures Analysis on Sepax Columns - View application note |
| Rituximab analysis using Zenix-C Light Scattering SEC -MALS 300 - View application note |
| Analytical Characterization of Monoclonal Antibody IgG2 - View application note |
| Eylea-Aflibercept - View application note |
| Analysis of Dextran Sulfate on Zenix-C SEC-300 (3µm, 300Å, 7.8x300mm) - View application note |
| Herceptin Analysis on ZenixTM SEC-300 (7830) - View application note |
| Human Serum on Zenix-C 300 and Proteomix SAX-NP3 - View application note |
| Literature Reference: Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study - View application note |
| Literature Reference: Structural Insights Into CXCR4 Modulation and Oligomerization - View application note |
| Literature Reference: Homogeneous Antibody-Drug Conjugates: DAR 2 Anti-HER2 Obtained by Conjugation on Isolated Light Chain Followed by mAb Assembly - View application note |